The Annexure

News to 16 October 2026 ·

Desk›Healthcare› Solara Active Pharma Sciences Ltd

Solara Active Pharma Sciences Ltd

BSE 541540 · NSE SOLARA · ISIN INE624Z01016 · Group B · Active

Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

₹621.10

+1.60%

BSE close, 28 August 2026

Market cap

₹2,968.52 cr

4.8 cr shares · Micro cap

Free float

₹1,507.66 cr

as published

P/E · P/B

-3,881.9× · 2.75×

EPS ₹-0.16 · BV ₹225.85

FY25-26 rev / PAT

1,368.98 / -7.24

₹ cr, as filed

Filings, window

25

4 selected · 16%

Regime

Reg 30

Sch. III Part A

Price 52-week, BSE

52-WK LOW ₹422.85 52-WK HIGH ₹711.20 ₹621.10 69% of range
Against 52-week high-12.7%
Against 52-week low+46.9%
Day change+1.60%
Size bandMicro cap
Index membershipNone

Valuation as published by BSE

Earnings per share₹-0.16
Price / earnings-3,881.88×
Price / book2.75×
Book value — derived, price ÷ P/B₹225.85
Return on equity-0.07%
Operating margin16.75%
Net margin4.45%

Consistency check

P/B ÷ P/E, which must equal ROE
-0.07%
ROE as published
-0.07%

Results ₹ crore, as filed

RevenueNet profit one scale across all three periods, ₹ crore

PeriodRevenue ₹cr Net profit ₹cr EPS ₹OPM NPM
Jun-26 · Q 381.60 16.99 3.67 16.75% 4.45%
Mar-26 · Q 387.29 9.73 2.23 16.22% 2.51%
FY25-26 1,368.98 -7.24 -1.64 13.64% -0.53%

Quarter on quarter

Revenue, quarter on quarter
-1.5%
Net profit, quarter on quarter
+74.6%
Operating margin, quarter on quarter
+53 bps

Disclosure profile 25 filings in the window

0 median 17.0 p75 · 24 sector max 59 25 79th percentile of 300 Healthcare filers
Shaded is the middle half of the sector, 12 to 24 filings. Measured against the 300 Healthcare companies that filed at all in this window — companies with no filings are excluded, so this is a percentile against filers rather than against the sector.
TagFilings
Selected
Board Outcome1
Concall Transcript1
Press Release1
Results1
Selected sub-total4
Procedural
General5
AGM / EGM3
Analyst / Investor Meet2
ESOP Allotment2
Newspaper Publication2
Annual Report1
BRSR1
Board Meeting1
Compliance Certificate1
Monitoring Agency1
Other Update1
Trading Window1
Procedural sub-total21
Total25

Disclosure regime

LODR Reg 30

Read with Schedule III Part A. An equity filer in BSE Group B, so the Regulation 30 disclosure framework and the Schedule III event list both apply.

Sources Price, day change, 52-week range — bse.quote, bse.quoteWeeklyHL, 28 August 2026 close. Market cap and free float — bse.getScripTradingStats. P/E, P/B, EPS, ROE, margins — bse.equityMetaInfo. Quarterly and annual results — bse.resultsSnapshot, standalone, as filed. Four-tier classification — data/reference/companies.csv. Filing counts and tags — the build aggregate for this window. Notes Book value is derived as price ÷ P/B; BSE does not publish it directly. Share count is derived as market cap ÷ price. Figures move between captures and between vendors, and the two are not an error in either: companies.csv carries the market cap from an earlier sweep than the snapshot above. EPS appears twice with different meanings — the figure beside P/E is the trailing one from equityMetaInfo, while the EPS in the results table is the per-period figure as filed.

Filing rhythm · 98 trading days

25 filings · 4 selected · busiest 2026-10-16

Filing rhythm · the twelve most recent

2026-10-092026-10-16

SelectedProcedural

Filings

25 in the window · 25 earlier on record

  1. 16 October 2026 ·

    Monitoring Agency

    Monitoring Agency Report

    Monitoring Agency Report for the quarter ended September 30, 2026

    Company Update / Monitoring Agency Report View filing →

  2. 16 October 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Outcome

    Audio recordings of Q2 FY27 earnings call conducted on October 16, 2026, for the quarter ended September 30, 2026

    Company Update / Analyst / Investor Meet View filing →

  3. 16 October 2026 ·

    Other Update

    Statement Of Deviation / Variation In Utilization Of Funds Raised For The Quarter Ended September 30, 2026.

    Solara Active Pharma Sciences Limited has informed the exchange about the Statement of Deviation/Variation in utilization of funds raised though Rights issue for the quarter ended September 30 2026

    Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation View filing →

  4. 16 October 2026 ·

    General

    Grant Of Employee Stock Options Under Solara Employee Stock Option Plan 2024.

    Solara Active Pharma Sciences Limited has informed the Exchange regarding grant of 470000 options under Solara Employee Stock Option Plan 2024

    Company Update / General View filing →

  5. 16 October 2026 ·

    Press Release

    Press Release / Media Release

    Solara Active Pharma Sciences Limited has informed the Exchange regarding a Press Release dated October 16, 2026, titled "Solara's Q2 FY 27 revenue grows 33% to INR 4,178 Mn and EBITDA ....

    Company Update / Press Release / Media Release View filing →

  6. 16 October 2026 ·

    ESOP Allotment

    Allotment of ESOP / ESPS

    Solara Active Pharma Sciences Limited has informed the Exchange regarding allotment of 8,300 Equity shares pursuant to exercise of ESOP options.

    Company Update / Allotment of ESOP / ESPS View filing →

  7. 16 October 2026 ·

    Results

    Outcome Of Board Meeting - Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026.

    Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter ....

    Result / Financial Results View filing →

  8. 16 October 2026 ·

    Board Outcome

    Board Meeting Outcome for Outcome Of Board Meeting - Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026.

    Solara Active Pharma Sciences Limited has informed the exchange regarding inter alia, to consider and approve the unaudited Standalone and Consolidated Financial Results for the quarter ....

    Board Meeting / Outcome of Board Meeting View filing →

  9. 13 October 2026 ·

    Analyst / Investor Meet

    Analyst / Investor Meet - Intimation

    Solara Active Pharma Sciences Limited has informed the Exchange about the Schedule of Investors/Analysts call to be held on Friday, October 16, 2026, at 4.00 PM IST to discuss the Company's ....

    Company Update / Analyst / Investor Meet View filing →

  10. 9 October 2026 ·

    General

    Update On Rights Issue - Final Reminder Cum Forfeiture Notice

    Update on approval of Final Reminder cum Forfeiture Notice for payment of outstanding call money.

    Company Update / General View filing →

  11. 9 October 2026 ·

    Board Meeting

    Board Meeting Intimation for Quarter And Half Year Ended September 30, 2026

    Solara Active Pharma Sciences Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/10/2026 ,inter alia, to consider and approve unaudited financial ....

    Board Meeting / Board Meeting View filing →

  12. 9 October 2026 ·

    Compliance Certificate

    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Solara Active Pharma Sciences Limited has informed the Exchange about Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the quarter ended ....

    Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 View filing →

  13. 25 September 2026 ·

    Trading Window

    Closure of Trading Window

    Intimation regarding Closure of Trading window for the quarter ended September 30, 2026

    Insider Trading / SAST / Closure of Trading Window View filing →

  14. 22 September 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Solara Active Pharma Sciences Limited has informed the exchange regarding the Voting Results and the Scrutinizer's report of the Ninth Annual General Meeting

    AGM/EGM / AGM View filing →

  15. 18 September 2026 ·

    AGM / EGM

    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Solara Active Pharma Sciences Limited has informed the Exchange regarding the Proceedings of Ninth Annual General Meeting held on September 18, 2026.

    AGM/EGM / AGM View filing →

  16. 28 August 2026 ·

    General

    Intimation In Connection With The Receipt Of Rectification Order

    Solara Active Pharma Sciences Limited has informed the exchange about intimation in connection with the receipt of Rectification Order

    Company Update / General View filing →

  17. 26 August 2026 ·

    Newspaper Publication

    Newspaper Publication

    Newspaper publication regarding the completion of dispatch of 9th AGM Notice and Annual report

    Company Update / Newspaper Publication View filing →

  18. 25 August 2026 ·

    BRSR

    Business Responsibility and Sustainability Reporting (BRSR)

    Business Responsibility and Sustainability Reporting for the financial year 2025-26.

    Others / Business Responsibility and Sustainability Reporting (BRSR) View filing →

  19. 25 August 2026 ·

    Annual Report

    Reg. 34 (1) Annual Report.

    Annual Report for the financial year ended March 31, 2026

    Others / Reg. 34 (1) Annual Report View filing →

  20. 25 August 2026 ·

    AGM / EGM

    Notice Of The Ninth Annual General Meeting

    Solara Active Pharma Sciences Limited has informed the exchange about the dispatch of Notice of Ninth Annual General Meeting (AGM) of the Company scheduled to be held on Friday, September 18, 2026

    AGM/EGM / AGM View filing →

  21. 24 August 2026 ·

    Newspaper Publication

    Newspaper Publication

    Solara Active Pharma Sciences Limited has informed the stock exchange regarding the Newspaper publication with respect to the Ninth Annual General Meeting.

    Company Update / Newspaper Publication View filing →

  22. 19 August 2026 ·

    General

    Conversion Of Partly Paid-Up Rights Equity Shares Into Fully Paid-Up Equity Shares In Relation To The Rights Issue By The Company, Upon Receipt Of The Call Monies, As Applicable

    Conversion of Partly paid-up Rights Equity Shares into fully paid-up Equity shares in relation to the rights issue by the Company, upon receipt of Call Monies, as applicable.

    Company Update / General View filing →

  23. 18 August 2026 ·

    ESOP Allotment

    Allotment of ESOP / ESPS

    Solara Active Pharma Sciences Limited has informed the Exchange regarding allotment of 2250 equity shares pursuant to exercise of ESOP options

    Company Update / Allotment of ESOP / ESPS View filing →

  24. 7 August 2026 ·

    General

    Update With Respect To Our Intimation Dated July 23, 2026, Regarding Appointment Of CIO And SMP Of The Company.

    Solara Active Pharma Sciences Limited has informed the exchange regarding the update with respect to our intimation dated July 23, 2026, regarding appointment of Chief Information Officer ....

    Company Update / General View filing →

  25. 29 July 2026 ·

    Concall Transcript

    Earnings Call Transcript

    Transcript of Earnings Conference call pertaining to financial results of the Company for the quarter ended June 30, 2026

    Company Update / Earnings Call Transcript View filing →

RSS feed for Solara Active Pharma Sciences Ltd · the 50 most recent filings